Opinion statement
Neuropathic pain is notoriously variable in its severity and impact on patients, as well as in its response to treatment. Certain therapies for neuropathic pain have better evidence for their use; however, it is apparent that although some therapies provide relief for only a minority of patients, the relief may be significant. Without a trial of therapy, there is no way to know if that relief is achievable. Our treatment experiences have shown that occasionally unexpected benefit is obtained through a thorough investigation of all options, even in the setting of failure of those with the most compelling evidence or indication. Chronic neuropathic pain is generally best treated with regularly dosed medications, balancing efficacy and tolerability. Evidence supports first-line trials of anticonvulsants, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors, alone or in certain combinations. While opioid medications, particularly methadone, can be effective in treating neuropathic pain, they are best used only in refractory cases and by experienced clinicians, due to concerns for both short- and long-term safety. Some therapies have a long history of successful use for certain syndromes (e.g., carbamazepine for trigeminal neuralgia pain), but these should not be considered to the exclusion of other more recent, less-supported therapies (e.g., botulinum toxin A for the same), particularly in refractory cases. We find the principles of palliative care highly applicable in the treatment of chronic neuropathic pain, including managing expectations, mutually agreed-upon meaningful outcomes, and a carefully cultivated therapeutic relationship.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Treede RD et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–5.
Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2010;3:CD007076.
Moore RA, Wiffen PJ, Derry S, Toelle T, Rice ASC. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;4:CD007938.
Harden N, Cohen M. Unmet needs in the management of neuropathic pain. J Pain Sym Manage. 2003;25(5 Suppl):S12–7.
Backonja M-M. Anticonvulsants (antineuropathics) for neuropathic pain syndromes. Clin J Pain. 2000;16(2 Suppl):S67–72.
Gilron I, Bailey JM, Tu D, Holden RH, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomized controlled crossover trial. Lancet. 2009;374(9697):1252–61.
Cruccu G, Gronseth G, Alksne J, Argoff C, Brainin M, Burchiel K, et al. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15(10):1013–28. Guidelines helpful in diagnosis and treatment of trigeminal neuralgia.
Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Oxcarbazepine for neuropathic pain. Cochrane Database Syst Rev. 2013;3:CD007963.
Wiffen PJ, Derry S, Moore RA, Kalso EA. Carbamazepine for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2014;4:CD005451.
Finnerup NB et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–73. Extensive review with references of anti-neuropathic agents.
Dong X, Leppik IE, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology. 2005;65(12):1976–8.
Liamis G, Milionis H, Esilaf M. A review of drug-induced hyponatremia. Am J Kidney Dis. 2008;52(1):144–53.
Gomez-Arguelles JM, Dorado R, Sepulveda JM, Herrera A, Arrojo FG, Aragon E, et al. Oxcarbazepine monotherapy in carbamazepine-unresponsive trigeminal neuralgia. J Clin Neurosci. 2008;15(5):516–9.
Carrazana E, Mikoshiba I. Rationale and evidence for the use of oxcarbazepine in neuropathic pain. J Pain Symptom Manage. 2003;25(5 Suppl):S31–5.
Mika J, Zychowska M, Makuch W, Rojewska E, Przewlocka E. Neuronal and immunological basis of action of antidepressants in chronic pain—clinical and experimental studies. Pharmacol Rep. 2013;65(6):1611–21.
Baltenberger EP, Buterbaugh WM, Martin BS. Review of antidepressants in the treatment of neuropathic pain. Ment Health Clinician. 2015;5(3):123–33.
Guay DR. Adjunctive agents in the management of chronic pain. Pharmacotherapy. 2001;21(9):1070–81.
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;4:CD005454.
Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012;12:CD008242.
Lunn MPT, Hughes RAC, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain, or fibromyalgia. Cochrane Database Syst Rev. 2014;1:CD007115.
Boyle J, Eriksson ME, Gribble L, Gouni R, Johnsen S, Coppini DV, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain. Diabetes Care. 2012;35(12):2451–8.
Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC. Venlafaxine for neuropathic pain (protocol). Cochrane Database Syst Rev. 2014;4:CD011091.
Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry. 2000;57(5):503–9.
Kelsey JE. Dose-response relationship with venlafaxine. J Clin Psychopharmacol. 1996;16(3 Suppl 2):21S–6S.
Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromusc Dis. 2001;3(2):53–62.
Vranken JH. Elucidation of pathophysiology and treatment of neuropathic pain. Cent Nerv Syst Agents Med Chem. 2012;12(4):304–14.
McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2013;8:CD006146.
Moulin DE et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manage. 2014;19(6):328–35.
Franklin GM. Opioids for chronic noncancer pain: a position paper from the American Academy of Neurology. Neurology. 2014;83(14):1277–84. Extensive review with references of anti-neuropathic agents.
Moulin DE, Palma D, Watling C, Schulz V. Methadone in the management of intractable neuropathic noncancer pain. Can J Nerol Sci. 2005;32(3):340–3.
Altier N, Dion D, Boulanger A, Choiniere M. Management of chronic neuropathic pain with methadone: a review of 13 cases. Clin J Pain. 2005;21(4):364–9.
Morley JS, Bridson J, Nash TP, Miles JB, White S, Makin MK. Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled cross-over trial. Pall Med. 2003;17(7):576–87.
Gagnon B, Almahrezi A, Schreier G. Methadone in the treatment of neuropathic pain. Pain Res Manage. 2003;8(3):149–54.
Texeira MJ et al. Methadone in post-herpetic neuralgia: a pilot proof-of-concept study. Clinics. 2013;68(7):1057–60.
Chou R, Weimer M, Dana T. Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence Clinical Practice Guideline. J Pain. 2014;15(4):338–65.
Attal N, Bouhassira D. Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms? Pain. 2015;156 Suppl 1:S104–14. Extensive review with references of anti-neuropathic agents.
Finnerup NB, Attal N. Tapentadol prolonged release in the treatment of neuropathic pain related to diabetic polyneuropathy—author’s reply. Lancet Neurol. 2015;14(7):685–6.
Wolff M, Schnöbel-Ehehalt R, Mühling J, Weigand MA, Olschewski A. Mechanisms of lidocaine’s action on subtypes of spinal dorsal neurons subject to the diverse roles of Na+ and K+ channels in action potential generation. Anesth Analg. 2014;119(2):463–70.
Werdehausen R et al. Lidocaine metabolites inhibit glycine transporter 1. A novel mechanism for the analgesic action of systemic lidocaine? Anesthesiology. 2012;116(1):147–58.
Brinkrolf P, Hahnenkamp K. Systemic lidocaine in surgical procedures: effects beyond sodium channel blockade. Curr Opin Anesthesiol. 2014;27(4):420–5.
Challapalli V, Tremont-Lukats IW, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev. 2005;4:CD003345.
Attal N, Gaudé V, Brasseur L, Dupuy M, Guirimand F, Parker F, et al. Intravenous lidocaine in central pain: a double-blind, placebo-controlled, psychophysical study. Neurology. 2000;54(3):564–74.
Viola V, Newnham HH, Simpson RW. Treatment of intractable painful diabetic neuropathy with intravenous lignocaine. J Diab Comp. 2006;20(1):34–9.
Finnerup NB et al. Intravenous lidocaine relieves spinal cord injury pain: a randomized controlled trial. Anesthesiology. 2005;102(5):1023–30.
Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology. 1991;41(7):1024–8.
Tremont-Lukats IW, Hutson PR, Backonja MM. A randomized, double-masked, placebo-controlled pilot trial of extended IV lidocaine infusion for relief of ongoing neuropathic pain. Clin J Pain. 2006;22(3):266–71.
Schwartzman RJ, Patel M, Grothusen JR, Alexander GM. Efficacy of 5-day continuous lidocaine infusion for the treatment of refractory complex regional pain syndrome. Pain Medicine. 2009;10(2):401–12.
Wu CL. Analgesic effects of intravenous lidocaine and morphine on post-amputation pain: a randomized double-blind, active placebo-controlled, crossover trial. Anesthesiology. 2002;96(4):841–8.
Raphael JH, Southall JL, Treharne GJ, Kitas GD. Efficacy and adverse effects of intravenous lignocaine therapy in fibromyalgia syndrome. BMC Musculoskelet Disord. 2002;3:21.
Ferrini R. Clinical Practice Guideline: the use of lidocaine infusion in inpatient and home care settings. AAHPM Bulletin. 2001;1(2):1–15.
Sleigh J, Harvey M, Voss L, Denny B. Ketamine—more mechanisms of action than just NMDA blockade. Trends Anaesth Crit Care. 2014;4(2–3):76–81.
Blonk MI et al. Use of oral ketamine in chronic pain management: a review. Eur J Pain. 2010;14(5):466–72.
Eichenberger U et al. Chronic phantom limb pain: the effects of calcitonin, ketamine, and their combination on pain and sensory thresholds. Anesth Analg. 2008;106(4):1265–73.
Collins S et al. NMDA receptor antagonists for the treatment of neuropathic pain. Pain Medicine. 2010;11:1726–42.
Birklein F, O’Neill D, Schlereth T. Complex regional pain syndrome: an optimistic perspective. Neurology. 2015;84(1):89–96.
Azari P, Lindsay DR, Briones D, Clarke C, Buchheit T, Pyati S. Efficacy and safety of ketamine in patient with complex regional pain syndrome. CNS Drugs. 2012;26(3):215–28.
Sawynok J. Topical and peripheral ketamine as an analgesic. Anesth Analg. 2014;119(1):170–8.
Prommer EE. Ketamine for pain: an update of uses in palliative care. J of Pall Med. 2012;15(4):474–83.
Vo T, Rice ASC, Dworkin R. Non-steroidal anti-inflammatory drugs for neuropathic pain: how do we explain continued widespread use? Pain. 2009;143(3):169–71.
Moore RA, Chi CC, Wiffen PJ, Derry S. Oral nonsteroidal anti-inflammatory drugs for neuropathic pain (protocol). Cochrane Database Syst Rev. 2013;12:CD010902.
Lanas A, Garcia-Tell G, Armada B, Oteo-Alvaro A. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis. BMC Medicine. 2011;9:38.
Trelle S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.
Romundstad L. Glucocorticoids for acute and persistent postoperative neuropathic pain what is the evidence? Anesthesiology. 2007;107(3):371–3.
Gray P. Acute neuropathic pain: diagnosis and treatment. Curr Opin Anaesthesiol. 2008;21(5):590–5.
Armon C, Argoff CE, Samuels J, Backonja MM. Assessment: use of epidural steroid injections to treat radicular lumbosacral pain. Neurology. 2007;68(10):723–9.
Dworkin RH et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237–51.
O’Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med. 2009;122(10 Suppl):S22–32.
Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol. 2003;43(2):111–7.
Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107(4):490–502.
Derry S, Rice ASC, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2013;2:CD007393.
Dobson JL, McMillan L, Li L. Benefits of exercise intervention in reducing neuropathic pain. Front Cell Neurosci. 2014;8:102.
Akyuz G, Kenis O. Physical therapy modalities and rehabilitation techniques in the management of neuropathic pain. Am J Phys Med Rehabil. 2014;93(3):253–9.
Allen N, Moloney N, van Vilet V, Canning CG. The rationale for exercise in the management of pain in Parkinson’s disease. J Parkinsons Dis. 2015;5:229–39.
Balducci S, Iacobellis G, Parisi L, Di Biase N, Calandriello E, Leonetti F, et al. Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Complications. 2006;20(4):216–23.
Dixit S, Maiya AG, Shastry BA. Effect of aerobic exercise on peripheral nerve functions of population with diabetic peripheral neuropathy in type 2 diabetes: a single blind, parallel group randomized controlled trial. J Diabetes Complications. 2014;28(3):332–9.
Kluding PM, Pasnoor M, Singh R, Jernigan S, Farmer K, Rucker J, et al. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J Diabetes Complications. 2012;26(5):424–9.
Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain: a double blind placebo controlled study. Ann Neurol. 2008;64(3):274–83.
Apalla Z, Sotirou E, Lallas A, Lazaridou E, Ioannides D. Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin J Pain. 2013;29(10):857–64.
Wu CJ, Lian YJ, Zheng YK, Zhang HF, Chen Y, Xie NC, et al. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2012;32(6):443–50.
Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009;72(17):1473–8.
Koppel B, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders. Neurology. 2014;82(17):1556–63.
Turk DC, Audette J, Levy RM, Mackey SC, Stanos S. Assessment and treatment of psychosocial comorbidities in patients with neuropathic pain. Mayo Clin Proc. 2010;85(3 Suppl):S42–50.
Moseley GL. Using visual illusion to reduce at-level neuropathic pain in paraplegia. Pain. 2007;130(3):294–8.
Lee MM, Cho HY, Song CH. The mirror therapy program enhances upper-limb motor recovery and motor function in acute stroke patients. Am J Phys Med Rehabil. 2012;91(8):689–700.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Matthew T. Mendlik and Tanya J. Uritsky declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Neurologic Manifestations of Systemic Disease
Rights and permissions
About this article
Cite this article
Mendlik, M.T., Uritsky, T.J. Treatment of Neuropathic Pain. Curr Treat Options Neurol 17, 50 (2015). https://doi.org/10.1007/s11940-015-0381-2
Published:
DOI: https://doi.org/10.1007/s11940-015-0381-2
Keywords
- Neuropathic pain
- Diabetic peripheral neuropathy (DPN)
- Post-herpetic neuralgia (PHN)
- Radiculopathy
- Central post-stroke pain
- Multiple sclerosis
- Fibromyalgia
- Complex regional pain syndrome
- Anticonvulsants
- Antidepressants
- Opioids
- Lidocaine
- Ketamine
- NSAIDs
- Corticosteroids
- Capsaicin
- Botulinum toxin
- Cannabinoids
- Complementary and alternative therapies